Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06024993

Dead Space in Mechanical Ventilation With Constant Expiratory Flow

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
13 (estimated)
Sponsor
University Hospital, Antwerp · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Conventional continuous mandatory mechanical ventilation relies on the passive recoil of the chest wall for expiration. This results in an exponentially decreasing expiratory flow. Flow controlled ventilation (FCV), a new ventilation mode with constant, continuous, controlled expiratory flow, has recently become clinically available and is increasingly being adopted for complex mechanical ventilation during surgery. In both clinical and pre-clinical settings, an improvement in ventilation (CO2 clearance) has been observed during FCV compared to conventional ventilation. Recently, Schranc et al. compared flow-controlled ventilation with pressure-regulated volume control in both double lung ventilation and one-lung ventilation in pigs. They report differences in dead space ventilation that may explain the improved CO2 clearance, although their study was not designed to compare dead space ventilation within the group of double lung ventilation. Dead space ventilation, or "wasted ventilation", is the ventilation of hypoperfused lung zones, and is clinically relevant, as it is a strong predictor of mortality in patients with the acute respiratory distress syndrome (ARDS) and is correlated with higher airway driving pressures which are thought to be injurious to the lung (lung stress). This trial aims to study the difference in dead space ventilation between conventional mechanical ventilation in volume-controlled mode and flow controlled-ventilation.

Conditions

Interventions

TypeNameDescription
DEVICEFlow-controlled ventilation (FCV)20 minutes of FCV, delivered with the CE-marked Evone ventilator (Ventinova medical, the Netherlands)
DEVICEConventional volume-controlled ventilation (VCV)20 minutes of conventional VCV, delivered with the CE-marked Aisys CS3 (GE Healthcare, USA) or Flow-i (Getinge, Sweden) ventilators.

Timeline

Start date
2024-07-22
Primary completion
2025-12-30
Completion
2026-04-30
First posted
2023-09-06
Last updated
2025-01-22

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06024993. Inclusion in this directory is not an endorsement.